National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Defibrotide (Defitelio®) indicated in adults, children and infants (>1month) for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy.

Rapid Review

Commenced Completed Outcome
12/05/2014 10/07/2014 Full Pharmacoeconomic Evaluation Recommended at the Submitted Price

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.